N-3c01(q2w)

Preclinical

HHefei Xinzhu Biological Technology Co., Ltd.

N-3c01(q2w) is one of 4 therapeutic programs targeting Advanced Malignant Solid Tumors. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Advanced Malignant Solid TumorsRecruiting

Advanced Malignant Solid TumorsPreclinical

Recruiting

Competition

Competitive Landscape

7 competitors in Advanced Malignant Solid Tumors

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Preclinical

1 2

JS207

SShanghai Junshi Bioscience Co., Ltd.

Phase 1

2 3

SCTB41

SSinocelltech Ltd.

Preclinical

1 4

N-3c01(q2w)

HHefei Xinzhu Biological Technology Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

PreclinicalRecruiting

Advanced Malignant Solid Tumors

NCT07639450

Clinical

Trials by Indication[1]

Advanced Malignant Solid Tumors1 trial

A Phase I/II Clinical Study Evaluating the Safety, Tolerability, and Efficacy of N-3C01 as Monotherapy and in Combination With PD-(L)1 Monoclonal Antibody in Patients With Advanced Malignant Solid Tumors

Recruiting·HHefei Xinzhu Biological Technology Co., Ltd.·Preclinical·NCT07639450·114 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for N-3c01(q2w). U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for N-3c01(q2w). EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Hefei Xinzhu Biological Technology Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: HHefei Xinzhu Biological Technology Co., Ltd.

N-3c01(q2w)

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Advanced Malignant Solid Tumors1 trial

References

Drug Info

Quick Facts

Related News